Articles & Research
from hVIVO

Challenges in Respiratory Clinical Trials

Challenges in Clinical Research in Respiratory Diseases: Insights from the European Respiratory Society Congress Clinical research in respiratory diseases plays a pivotal role in advancing our understanding of various conditions,...

Tripledemic Takedown: How Human Challenge Trials are Ideal to Expedite Multivalent Vaccine Development

Introduction The recent rise of the "tripledemic" – the concurrent spread of the influenza virus, SARS-CoV-2 virus, and respiratory syncytial virus (RSV) – is posing significant risks, especially to older...

Human SARS-CoV-2 challenge uncovers local and systemic response dynamics | Nature

Controlled Human Infection Model's (CHIM) in your backpack: how Human Challenge Trials support regulatory approval of travel vaccines

Introduction A ‘travellers vaccine’ is a vaccine administered to travellers from a ‘non-endemic region’, before they visit an endemic region, and they form an important component of travel medicine. Beyond...

Scientific Paper

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single centre, open-label, phase 1 controlled human infection study

A SARS-CoV-2 controlled human infection model (CHIM) has been successfully established in seronegative individuals using a dose of 1×101 50% tissue culture infectious dose (TCID50) pre-alpha SARS-CoV-2 virus. Given the...

SARS-CoV-2 Human Challenge Study

At the start of the Covid pandemic, as the world leader in human challenge studies, hVIVO acted as prime contractor in a UK Government funded consortium tasked with setting up...

Human Challenge Trials for Tropical Diseases: Not as exotic as one might think

Introduction Despite scientific progress made in the last decades, nearly 1 billion of individuals are affected by tropical diseases yearly, according to the World Health Organization. The development of new...

Scientific Paper

Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults

Co-authored by Alexander Mann – Senior Director of Clinical Science, Andrew Catchpole – Chief Scientific Officer, Mariya Kalinova – Medical Director

Influenza Phase IIa Challenge Study Case Study

hVIVO were contracted by a US-based clinical-stage biopharmaceutical company to conduct an Influenza Phase IIa challenge study with their investigational product. Their lead candidate was a first-in-class, broadly neutralising anti-influenza...

The UK Regulatory Competitiveness in an ever changing world

Clinical research success during the COVID-19 pandemic The United Kingdom, with its rich history of clinical trials, has long been a preferred destination for conducting cutting-edge research. One of the...